Pharmacogenetics in the rheumatic diseases

Annals of the Rheumatic Diseases

Volumn 63, Issue SUPPL. 2, 2004, Pages

  Cronstein, B N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE;

CONFERENCE PAPER; DRUG EFFICACY; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; HUMANS; PHARMACOGENETICS; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 7044253001     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.028217     Document Type: Conference Paper

References (24)

1. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001;193:1159-67.
2. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2003;48:571-2.
3. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine. Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:656-63.
4. Silke C, Murphy MS, Buckley T, Busteed S, Molloy MG, Phelan M. The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology (Oxford) 2001;40(suppl 1):34.
5. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford) 2004;43:13-18.
6. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
7. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003;11:593-600.
8. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90.
9. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
10. Dervieux T, Lein DO, Park G, Barham R, Smith K, Walsh M, et al. Single nucleotide polymorphisms (SNPs) in the folate/purine pathway predict methotrexate's effects in rheumatoid arthritis. Arthrits Rheum 2003;48(suppl):1093.
11. Dijkmans BA. Folate supplementation and methotrexate. Br J Rheumatol 1995;34:1172-4.
12. Cooper BA. Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 1996;124(1 Pt 1):73; discussion 74.
13. Kavanaugh A, Kavanaugh D. Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 1996;124(1 Pt 1):73; discussion 74.
14. Shiroky JB. Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 1996;124(1 Pt 1):73-4.
15. Shiroky JB. The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin North Am 1997;23:969-80.
16. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 1997;24:2230-2.
17. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25:36-43.
18. Morgan SL, Baggott JE, Lee JY, Alarcon GS. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25:441-6.
19. Pincus T. Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol 1998;16:667-8.
20. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999;17:625-7.
21. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD000951.
22. van Ede AE, Loan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
23. Endresen GK, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines. Scand J Rheumatol 2001;30:129-34.
24. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with Rheumatoid Arthritis. Arthritis Rheum 1990;33:9-18.